Drug intelligence / Profile preview

Novel PKRi

Development stage: Preclinical
Lead developer: Transposon Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Novel PKRi is a preclinical-stage small molecule inhibitor of protein kinase R (PKR), also known as EIF2AK2, being developed by Transposon Therapeutics. The program targets PKR pathways that are pathologically activated by the expression of LINE-1 (Long Interspersed Nuclear Element-1) retrotransposons. LINE-1 activation is associated with neuroinflammation and the cellular stress response, which are implicated in the pathogenesis of various cognitive disorders. By inhibiting PKR, Transposon Therapeutics aims to mitigate these downstream effects and provide a therapeutic benefit for disorders of cognition. The asset is currently in the discovery and preclinical development phase.

Other names: PKR inhibitorProtein kinase R inhibitor

Targets

EIF2AK2 (Interferon-induced protein kinase R)

Beyond the preview

Go deeper on Novel PKRi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel PKRi.

Explore the full profile